These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report]. Bao L; Huang XJ Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):573. PubMed ID: 22967422 [No Abstract] [Full Text] [Related]
8. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781 [TBL] [Abstract][Full Text] [Related]
9. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072 [TBL] [Abstract][Full Text] [Related]
10. A review of 76 patients with myelodysplastic syndromes treated with danazol. Chabannon C; Molina L; Pégourié-Bandelier B; Bost M; Léger J; Hollard D Cancer; 1994 Jun; 73(12):3073-80. PubMed ID: 8200005 [TBL] [Abstract][Full Text] [Related]
12. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study. Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083 [TBL] [Abstract][Full Text] [Related]
13. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate]. Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071 [TBL] [Abstract][Full Text] [Related]
14. Danazol in the treatment of women with metastatic breast cancer. Brodovsky HS; Holroyde CP; Laucius JF; Dugery C; Serbin J Cancer Treat Rep; 1987 Sep; 71(9):875-6. PubMed ID: 3621223 [No Abstract] [Full Text] [Related]
16. Danazol and myelodysplastic syndromes. Kornberg A; Yona R; Iuklea S; Kaufman S Ann Intern Med; 1986 Mar; 104(3):445-6. PubMed ID: 3946991 [No Abstract] [Full Text] [Related]
17. [Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes]. Avilés A; Tripp F; Velásquez A; Rubio ME; González-Llavén J Rev Invest Clin; 1988; 40(1):21-4. PubMed ID: 3165541 [No Abstract] [Full Text] [Related]
18. Classification of the myelodysplastic syndromes. Bennett JM Clin Haematol; 1986 Nov; 15(4):909-23. PubMed ID: 3471370 [No Abstract] [Full Text] [Related]
19. [Clinical, hematologic and developmental characteristics of myelodysplastic syndromes. Study of a group of patients with a long-term follow-up]. Di Giovanni S; Giallonardo P; Costa MP; Carducci P Recenti Prog Med; 1987 Feb; 78(2):63-8. PubMed ID: 3473582 [No Abstract] [Full Text] [Related]
20. [Bestatin treatment of patients with myelodysplastic syndromes]. Uzuka Y; Saito Y Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):365-70. PubMed ID: 2930201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]